- Everything we could find out about it

Home ] [ Controlled Substances ] [ Opioids ]

Created Mar 2019 | Updated Oct 2020


  • [N]


DEA CODE 9822: Schedule 1 Narcotic

Synthetic Opioid

World Health Organization 2016:
  • Butyrfentanyl is a potent, short-acting mu opioid receptor agonist, and an analogue of fentanyl, differing by only one methyl group.
  • It has no approved medical indications, but is being used for recreational purposes, with cases of fatal overdoses reported in Europe and the United States. The actual extent of abuse and mortality associated with butyrfentanyl is not known because it is not tested for in routine toxicological analyses.
  • Typically used as a nasal spray, snorted as a white power, or injected intravenously, and doses range from 0.5 to 3 mg.
  • The effects appear to be similar to the effects of fentanyl, including euphoria, altered mood states, drowsiness, and respiratory depression.
  • Studies suggest that butyrfentanyl is about 30 times less potent than fentanyl
  • Butyrfentanyl is being abused for its opioid effects.
  • No accepted medical purpose has been identified.


Potent short-acting opioid and fentanyl analogue. Often dispensed in a nasal spray. This is an highly potent drug - exercise extreme caution. May cause respiratory depression and death in overdose.

NOTE: It's a potent drug, be careful.

RouteOnsetDurationAfter Effects
Tripsit Factsheets
Oral:15-30 minutes3-4 hours1-4 hours
Butyrfentanyl Duration
Avoid all other CNS depressants.
  • bf
  • b-f

  • A synthetic opioid analgesic
  • Potent
  • Short-acting
  • An analog of fentanyl with around one quarter of its potency
  • Side effects are similar to those of fentanyl itself
  • Butyrfentanyl binds to the opioid receptor

Butyrfentanyl has no current legitimate clinical applications; however, it is being sold as designer drug

Sevierville pair indicted for distributing fentanyl that led to East Tennessean's OD death - and butyryl fentanyl, a Schedule I controlled substance, that resulted in the death of an East Tennessee resident," the report said. Both face trial on May 28. If convicted of distribution of ...
Wednesday March 27, 2019 - wbir.com

Journal of analytical toxicology - Identification of Drugs in Parenteral Pharmaceutical Preparations from a Quality Assurance and a Diversion Program by Direct Analysis in Real-Time AccuTOFTM-Mass Spectrometry (DART-MS).
Thursday November 09, 2023 - medscape.com

Opioids | Link to this page

Home ] [ Controlled Substances ] [ Sources ]

· Controlled Substances
· Opioids
· Butyryl-fentanyl